|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients carrying the WISP1 rs2929973 GG + TT variant were almost twice as likely as those carrying the GT genotype to have estrogen receptor (ER)- and progesterone receptor (PR)-positive tumors, while those with the WISP1 rs62514004 AG + GG genetic variants were around twice as likely as those with the AA genotype to have HER2-positive tumors.
|
31689877 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Specifically, WISP1 directly binds to type I collagen to promote its linearization in vitro (in the absence of cells) and in vivo in tumors.
|
31294477 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>Methods</b>: Publicly available RNA-seq datasets were used to evaluate the prognostic value of WISP1 gene expression and its association with tumor-infiltrating lymphocytes, inflamed tumor microenvironment, and anti-PD-1 ICB response.
|
31069142 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further analyses revealed that a correlation between the expressions of WISP1 and invasive tumor and large tumor size in urothelial carcinoma was observed in the TCGA (The Cancer Genome Atlas) dataset.
|
29277583 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Its role in tumor progression and clinical outcome makes WISP1 an emerging candidate for the detection and treatment of tumors.
|
25794425 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also verified that the gains of MYC and WISP1 genes seem to suggest higher propensity of tumors localized in the floor of the mouth.
|
24477574 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IHC staining for ADAM12, FAP, and WISP1 correlated with CDR and was higher, whereas SOX11 staining was lower in tumors with earlier recurrence following excision.
|
24402778 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, WISP-1 and ICAM-1 expression correlated with the tumor stage of patients with OSCC.
|
24205072 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There were significantly more WISP-1-positive infiltrative type tumors than expanding type tumors.
|
21498727 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
WISP-1 transcripts were found at higher levels in the tumour samples than in the normal tissue (p=0.0015); higher in patients with Dukes stage B and C compared to Dukes A (p=0.017 and p=0.024, respectively); higher in patients with moderately and poorly differentiated cancers compared to the well differentiated cancers (p=0.020 and p=0.076, respectively and p=0.0035 when combined); higher in node positive tumours compared with the node negative (p=0.11) and in the patients with higher TNM staging (TNM 2, 3 and 4 compared to TNM 1 p=0.037).
|
20372786 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role.
|
17406949 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant correlation also existed between WISP-1 expression with tumor histology, and patient age.
|
17579708 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, significant associations were found between CTGF expression versus stage, tumor size, lymph node status, and age at diagnosis; WISP-1 mRNA levels versus stage, tumor size, lymph node, and HER-2/neu overexpression; and CYR61 expression with stage, tumor size, lymph node, age, and estrogen receptor expression.
|
11751417 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
WISP-1 genomic DNA was amplified in colon cancer cell lines and in human colon tumors and its RNA overexpressed (2- to >30-fold) in 84% of the tumors examined compared with patient-matched normal mucosa.
|
9843955 |
1998 |